Bioenvision stockholders approve aquisition by Genzyme

US biotechnology major Genzyme says that Bioenvision stockholders have voted to approve its acquisition at a reconvened special shareholder meeting in New York (Marketletters passim). The transaction became effective from October 23. Bioenvision shares have now ceased trading and the company will be delisted from Nasdaq. 56% of Bioenvision's issued and outstanding shares of common stock and preferred stock, voting together as a single class on an as converted basis, supported the merger.